SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form POS AM - Post-Effective amendments for registration statement:
SEC Accession No. 0001213900-20-000338
Filing Date
2020-01-07
Accepted
2020-01-07 10:51:01
Documents
4

Document Format Files

Seq Description Document Type Size
1 POST-EFFECTIVE AMENDMENT NO. 4 TO REGISTRATION STATEMENT posam2020a4_biondvaxpharma.htm POS AM 687207
2 OPINION OF PEARL COHEN ZEDEK LATZER BARATZ,, ISRAELI COUNSEL TO BIONDVAX PHARMAC posam2020a4ex5-1_biondvax.htm EX-5.1 8386
3 CONSENT OF EY posam2020a4ex23-1_biondvax.htm EX-23.1 2086
4 GRAPHIC image_001.jpg GRAPHIC 13945
  Complete submission text file 0001213900-20-000338.txt   717987
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: POS AM | Act: 33 | File No.: 333-201283 | Film No.: 20512502
SIC: 2836 Biological Products, (No Diagnostic Substances)